Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | BACE1 | P56817 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14430493 | 0.84 | POLB (0.35) | POLBLMNAALDH1A1 | |
| SCHEMBL5199517 | 0.77 | MAPK1 (0.40) | POLB | |
| SCHEMBL14430546 | 0.73 | MAPK1 (0.42) | POLBALDH1A1 | |
| SCHEMBL14430490 | 0.72 | SLC6A2 (0.37) | — | |
| SCHEMBL14430436 | 0.72 | SMN1; SMN2 (0.40) | LMNABACE1GAA | |
| SCHEMBL1266987 | 0.69 | OPRL1 (0.58) | SIGMAR1POLBLMNAALDH1A1 | |
| SCHEMBL5201301 | 0.69 | MAPK1 (0.41) | SIGMAR1BACE1ALDH1A1 | |
| SCHEMBL14430562 | 0.69 | MAPK1 (0.45) | SIGMAR1ALDH1A1 | |
| SCHEMBL25357912 | 0.68 | OPRL1 (0.52) | SIGMAR1POLBLMNAACHEBACE1 | |
| SCHEMBL14430450 | 0.67 | MAPK1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1795524-A1 | CYCLIC AMINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-06-13 | — | — | EP | disclosed |
| EP-1795524-A1 | CYCLIC AMINE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197594-A1 | Cyclic amine derivative or salt thereof | GRIN1, PARK7, GRIN3A | SIGMAR1 302/4885POLB 1383/4885LMNA 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.